申请人:Freyne Jean Edgard Eddy
公开号:US20070078132A1
公开(公告)日:2007-04-05
The present invention concerns the compounds of formula
the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein
a
1
-a
2
=a
3
-a
4
represents a divalent radical selected from N—CH═CH—CH, N—CH═N—CH or CH—CH═N—CH;
Z represents NH; Y represents —C
3-9
alkyl-, —C
1-5
alkyl-NR
13
—C
1-5
alkyl-, —C
1-6
alkyl-NH—CO— or —CO—NH—C
1-6
alkyl-;
X
1
represents —O— or —NR
11
—; X
2
represents —C
1-2
alkyl-, —O—C
1-2
alkyl, —O— or —O—CH
2
—;
R
1
represents hydrogen or halo;
R
2
represents hydrogen, cyano, halo, hydroxycarbonyl-, C
1-4
alkyloxycarbonyl-, Het
16
-carbonyl- or Ar
5
; R
3
represents hydrogen;
R
4
represents hydroxy, C
1-4
alkyloxy-, Ar
4
—C
1-4
alkyloxy or R
4
represents C
1-4
alkyloxy substituted with one or where possible two or more substituents selected from C
1-4
alkyloxy- or Het
2
-;
R
11
represents hydrogen;
R
12
represents hydrogen, C
1-4
alkyl- or C
1-4
alkyl-oxy-carbonyl-;
R
13
represents Het
14
-C
1-4
alkyl, in particular morpholinyl-C
1-4
alkyl;
Het
2
represents a heterocycle selected from morpholinyl or piperidinyl optionally substituted with C
1-4
alkyl-, preferably methyl;
Het
14
represents morpholinyl;
Het
16
represents a heterocycle selected from morpholinyl or pyrrolidinyl;
Ar
4
represents phenyl; Ar
5
represents phenyl optionally substituted with cyano.